Skip to main
CELC

Celcuity (CELC) Stock Forecast & Price Target

Celcuity (CELC) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Celcuity is progressing rapidly towards commercialization and is poised for success with its differentiated drug candidate, gedatolisib, in both breast and prostate cancers. The recent positive results from its Phase 3 VIKTORIA-1 trial, along with ongoing trials and regulatory submissions, indicate a strong potential for market adoption and potential peak sales. With a well-funded balance sheet and experienced management team, Celcuity is a promising investment in the competitive landscape of cancer therapeutics.

Bears say

Celcuity is expected to face intense market competition with its gedatolisib drug, and a higher price point of $30,000 per cycle may limit its market potential. Additionally, there are various risk factors, including clinical, regulatory, and financial risks, that could negatively impact the company's share price. While recent updates and milestones have shown promise, the success of the drug and the company's ability to obtain necessary approvals and financing remain uncertain.

Celcuity (CELC) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celcuity (CELC) Forecast

Analysts have given Celcuity (CELC) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Celcuity (CELC) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $153.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $153.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celcuity (CELC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.